MCL1 and acute myeloid leukemia: Earlier experiments in acute myeloid leukemia (AML) cell lines support our results, reporting that MCL-1 levels were downregulated by azacitidine and that this resistance mechanism could be overcome by additional BH3 mimetic treatment with ABT737 [40].